Non-stimulant ADHD medications include atomoxetine (Strattera), viloxazine (Qelbree), guanfacine ER (Intuniv) and clonidine ER (Kapvay), all FDA-approved, plus bupropion off-label. They take two to six weeks to work, are not controlled substances, and suit people with anxiety, substance use history, tics, cardiac concerns or stimulant side effects. They are modestly less effective than stimulants on average.
Stimulant medications, the methylphenidate and amphetamine families, have been the backbone of ADHD treatment for decades, and for good reason: they work for about 70 to 80 percent of people, within an hour, with a large evidence base. But a meaningful share of patients cannot take them, do not want them, or do not tolerate them. For those people, the non-stimulant options have become a real alternative rather than a consolation prize.
The non-stimulants, one by one
Atomoxetine (Strattera)
Atomoxetine was the first non-stimulant approved for ADHD, in 2002, for children and adults. It is a selective norepinephrine reuptake inhibitor, meaning it increases norepinephrine signaling in the prefrontal cortex, which improves attention and impulse control through a different route than stimulants. It is taken once or twice daily and works around the clock rather than in a dosing window.
It takes time. Most people notice initial effects within two to four weeks, with full effect at six to eight weeks, and the dose is increased gradually. Common side effects are nausea, reduced appetite, dry mouth, fatigue, and in men, sexual side effects. It carries an FDA warning about suicidal thoughts in children and adolescents, similar to antidepressants, and a rare risk of liver injury. It is a reasonable choice when anxiety accompanies ADHD, because it does not worsen anxiety and may help it.
Viloxazine (Qelbree)
Viloxazine was approved for ADHD in children in 2021 and adults in 2022. It is also a norepinephrine reuptake inhibitor with some serotonin activity, and it was previously used in Europe as an antidepressant. It is taken once daily in an extended-release capsule. Onset is similar to atomoxetine, with effects building over several weeks. Side effects include sleepiness, reduced appetite, nausea, headache and irritability, and it carries the same suicidality warning. It interacts with caffeine and some other medications by inhibiting a liver enzyme, which your prescriber will review.
Guanfacine extended-release (Intuniv)
Guanfacine ER is an alpha-2A adrenergic agonist, originally a blood pressure medication, approved for ADHD in children and adolescents aged 6 to 17. It is used off-label in adults. It works on prefrontal receptors that strengthen working memory and reduce impulsivity, and it is particularly useful for hyperactivity, emotional reactivity and sleep problems. It can be used alone or added to a stimulant. Side effects are sleepiness, fatigue, low blood pressure, dizziness and dry mouth; it should be tapered rather than stopped abruptly to avoid rebound high blood pressure. Onset is one to three weeks.
Clonidine extended-release (Kapvay)
Clonidine ER is a close relative of guanfacine, approved for ADHD in ages 6 to 17, alone or with a stimulant. It is more sedating than guanfacine, which makes it useful when insomnia or tics are prominent and less useful when daytime drowsiness is a problem. The same cautions about blood pressure and tapering apply.
Bupropion (Wellbutrin)
Bupropion is an antidepressant that increases dopamine and norepinephrine. It is not FDA-approved for ADHD but is widely used off-label in adults, with several trials showing modest benefit. It is a sensible choice when depression and ADHD coexist, or when a person wants to avoid both stimulants and the newer non-stimulants. It lowers the seizure threshold and is avoided in people with seizure disorders or eating disorders.
Side-by-side comparison
| Medication | FDA-approved for ADHD | Mechanism | Time to effect | Controlled substance | Notable side effects |
|---|---|---|---|---|---|
| Atomoxetine | Yes, ages 6 and up | Norepinephrine reuptake inhibitor | 2 to 8 weeks | No | Nausea, appetite loss, fatigue, sexual side effects |
| Viloxazine | Yes, ages 6 and up | Norepinephrine reuptake inhibitor | 2 to 6 weeks | No | Sleepiness, appetite loss, nausea, caffeine interaction |
| Guanfacine ER | Yes, ages 6 to 17; off-label adults | Alpha-2A agonist | 1 to 3 weeks | No | Sedation, low blood pressure, dizziness |
| Clonidine ER | Yes, ages 6 to 17; off-label adults | Alpha-2 agonist | 1 to 3 weeks | No | Sedation, low blood pressure, dry mouth |
| Bupropion | No (off-label) | Dopamine and norepinephrine reuptake inhibitor | 2 to 6 weeks | No | Insomnia, anxiety, seizure risk at high doses |
| Stimulants (for comparison) | Yes | Dopamine and norepinephrine release and reuptake inhibition | 30 to 60 minutes | Yes, Schedule II | Appetite loss, insomnia, elevated heart rate, irritability |
How effective are they compared with stimulants?
Honestly: somewhat less, on average. Meta-analyses consistently find that stimulants produce larger improvements in core ADHD symptoms than non-stimulants, with effect sizes roughly 0.9 to 1.0 for stimulants versus 0.6 to 0.7 for atomoxetine and the alpha agonists. That gap is real but it describes averages. Individual patients sometimes respond better to a non-stimulant than to any stimulant they tried, and for patients who cannot take stimulants, the comparison is between a non-stimulant and nothing.
Non-stimulants also have advantages that symptom scales do not capture: 24-hour coverage without the afternoon crash, no rebound irritability, no abuse potential, no need for a controlled-substance prescription each month, and, for guanfacine and clonidine, benefits for sleep and emotional regulation that stimulants can worsen.
When a non-stimulant is the better choice
- Anxiety alongside ADHD. Stimulants can amplify anxiety; atomoxetine and guanfacine often help it.
- Substance use history. Non-stimulants carry no misuse risk, which matters for the patient and for the prescriber.
- Tics or Tourette syndrome. Stimulants can worsen tics; guanfacine and clonidine can improve them.
- Cardiac concerns. Stimulants raise heart rate and blood pressure; the alpha agonists lower them. Atomoxetine also raises heart rate slightly, so it is not automatically safe for cardiac patients.
- Stimulant side effects. Insomnia, appetite suppression, irritability or a flat emotional feeling on stimulants.
- Insomnia or sleep-onset problems. Clonidine ER and guanfacine ER help.
- Preference. Some people simply do not want a controlled substance, and that is a legitimate reason.
- Telehealth logistics. Non-stimulants can be prescribed by telehealth without the in-person requirements that may apply to Schedule II stimulants.
Combining non-stimulants with stimulants
Guanfacine ER and clonidine ER are approved as add-ons to stimulants in children, and the combination is common in adults too. The pattern is a stimulant for daytime focus plus a low dose of an alpha agonist in the evening for sleep, emotional reactivity and the stimulant wear-off. Atomoxetine and stimulants are sometimes combined, though the evidence is thinner.
What to expect when starting
Unlike a stimulant, which you can judge in a day, a non-stimulant requires patience. Your clinician will start at a low dose, increase every one to two weeks, and ask you to track symptoms. The fair test is six to eight weeks at a full dose. Side effects usually appear early and fade; benefit appears late and builds. Stopping after two weeks because "nothing is happening" is the most common reason non-stimulants get labeled ineffective.
At Stedfast Psychiatry, non-stimulant ADHD medications are prescribed at all 13 offices in Florida and South Carolina and by telehealth. Follow-up is typically at two to four weeks, then monthly until the dose is stable.
Bottom line
Non-stimulant ADHD medications are slower and, on average, somewhat less powerful than stimulants, but they are effective, well studied, free of misuse risk and often the better match for people with anxiety, tics, cardiac issues, substance history or stimulant intolerance. The choice is clinical, not a ranking, and a good evaluation will tell you which category fits your situation.
Frequently asked questions
What is the best non-stimulant ADHD medication for adults?
Atomoxetine and viloxazine are the FDA-approved options for adults and are usually tried first. Guanfacine ER is widely used off-label in adults, especially when emotional reactivity or sleep problems are prominent. Bupropion is a reasonable choice when depression coexists. The best one depends on your symptom pattern and other conditions.
How long do non-stimulant ADHD medications take to work?
Two to eight weeks, depending on the drug. Guanfacine and clonidine act within one to three weeks; atomoxetine and viloxazine build over four to eight weeks at a full dose. A fair trial means staying on a therapeutic dose for at least six weeks before judging.
Are non-stimulants as effective as Adderall?
On average, no. Stimulants produce larger improvements in core symptoms in meta-analyses. However, individual responses vary, non-stimulants offer 24-hour coverage without crashes or misuse risk, and for people who cannot take stimulants the relevant comparison is non-stimulant versus no treatment.
Can non-stimulant ADHD medication be prescribed by telehealth?
Yes. None of the non-stimulants are controlled substances, so they can be prescribed by telehealth in Florida and South Carolina without the in-person requirements that may apply to stimulants. Stedfast Psychiatry prescribes them by video in both states.
Related reading
- How to Get Diagnosed With ADHD as an Adult
- Anxiety or ADHD? How to Tell the Difference
- Can a Psychiatrist Prescribe ADHD Medication Over Telehealth?
- ADHD Testing Near Me: What an Evaluation Actually Involves
This article is educational and does not replace evaluation by a licensed clinician. If you are in crisis, call or text 988.